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Extracellular signal-regulated kinase (ERK)1/2 activity is reported to be required in mammalian cells for timely entry into
and exit from mitosis (i.e., the G2-mitosis [G2/M] and metaphase-anaphase [M/A] transitions). However, it is unclear
whether this involvement reflects a direct requirement for ERK1/2 activity during these transitions or for activating gene
transcription programs at earlier stages of the cell cycle. To examine these possibilities, we followed live cells in which
ERK1/2 activity was inhibited through late G2 and mitosis. We find that acute inhibition of ERK1/2 during late G2 and
through mitosis does not affect the timing of the G2/M or M/A transitions in normal or transformed human cells, nor does
it impede spindle assembly, inactivate the p38 stress-activated checkpoint during late G2 or the spindle assembly
checkpoint during mitosis. Using CENP-F as a marker for progress through G2, we also show that sustained inhibition of
ERK1/2 transiently delays the cell cycle in early/mid-G2 via a p53-dependent mechanism. Together, our data reveal that
ERK1/2 activity is required in early G2 for a timely entry into mitosis but that it does not directly regulate cell cycle
progression from late G2 through mitosis in normal or transformed mammalian cells.
INTRODUCTION
The extracellular signal-regulated (ERK)1/2 pathway con-
sists of Raf1, mitogen-activated protein kinase kinase (MEK)1/2,
and ERK1/2 kinases, which upon pathway activation are
sequentially and specifically phosphorylated (Seger and
Krebs, 1995). Once activated, ERK1/2 phosphorylates nu-
merous cytoplasmic and nuclear substrates that lead to
diverse cellular responses, including proliferation and dif-
ferentiation, via both transcription-dependent and indepen-
dent mechanisms (Pearson et al., 2001; Yoon and Seger,
2006). Basically, ERK1/2 activity is essential for cell growth;
it mediates the G1/S transition by facilitating nucleotide and
protein syntheses as well as the transcription of cell cycle
regulators, including cyclins D and E (Widmann et al., 1999;
Roovers and Assoian, 2000). Not unexpectedly, constitutive
activation of ERK1/2 via mutations in Raf or its upstream
Ras G protein leads to uncontrolled cell growth, whereas the
inability to activate ERK1/2 is lethal in utero (Wojnowski et
al., 1998; Giroux et al., 1999) and inhibits the growth of
cultured cells (Pages et al., 1993).
In addition to its essential role in promoting the G1/S
transition, enhanced ERK1/2 activity is also required in
mammalian cells for a timely G2-mitosis (G2/M) transition.
Long-term (hours to days) suppression of ERK1/2 by using
pharmacological inhibitors of MEK1/2, dominant-negative
MEK1, or RNA interference (RNAi) produces a delay in
“G2/M” (Wright et al., 1999; Hayne et al., 2000; Roberts et al.,
2002; Liu et al., 2004; Knauf et al., 2006). Gene expression
profiling of nontransformed mammary epithelial cells also
reveals that constitutive activation of ERK1/2 via MEK1
leads to increased levels of mRNAs that encode mitotic
proteins such as Cyclin B, CDK1, CENP-E, Bub1, Mad2, and
Aurora A (Grill et al., 2004). Among these, Cyclin B is under
the control of the FoxM1 transcriptional factor (Alvarez et al.,
2001; Laoukili et al., 2005), and the ERK1/2 pathway has
recently been shown to activate one of its isoforms, FoxM1c
(Ma et al., 2005). Together, these data suggest that ERK1/2
activity plays an upstream role in regulating the G2/M
transition in mammalian cells by activating specific gene
expression pathways, and this regulation likely occurs dur-
ing early–mid-G2 before the transcriptional silencing seen in
late G2 and mitosis.
The notion that ERK1/2 also regulates progression through
the G2/M transition and mitosis in a transcription-independent
manner comes primarily from studies on Xenopus oocyte ex-
tracts. In this system, ERK1/2 activity is sufficient for activating
cyclin B/Cdk1, which induces the first meiotic division (Ferrell,
1999), and once in meiosis ERK1/2 seems to regulate spin-
dle bipolarity via its (direct or indirect) effects on micro-
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tubule dynamics (Gotoh et al., 1991; Guadagno and Fer-
rell, 1998; Horne and Guadagno, 2003). ERK1/2 activity is
also required in Xenopus oocyte extracts for a functional
spindle assembly checkpoint (SAC) (Minshull et al., 1994;
Takenaka et al., 1997; Chung and Chen, 2003) and likely
also in Xenopus tadpole cells (Wang et al., 1997).
As in Xenopus oocytes, there is evidence that ERK1/2 also
plays a nontranscriptional role in the G2/M transition in
transformed mammalian somatic cells. In this regard, sev-
eral biochemical and/or fluorescence-activated cell sorting
studies report that the activity of ERK1/2 is enhanced dur-
ing G2/M (e.g., Tamemoto et al., 1992; Wright et al., 1999;
Hayne et al., 2000; Roberts et al., 2002). The exact meaning of
this conclusion is, however, vague because the temporal
resolution of these studies is not sufficient to reveal whether
the enhancement of ERK1/2 activity occurs during late G2,
mitosis, or both. Indeed, although some workers report that
ERK1/2 pathway activity increases as cells transit into
and/or exit mitosis (Edelmann et al., 1996; Roberts et al.,
2002), others conclude that the activity of MEK (Laird et al.,
1999; Hayne et al., 2004) and ERK1/2 are depressed during
mitosis (Newberry and Pike, 1995; Klein et al., 1997; Gomez-
Cambronero, 1999; Harding et al., 2003) and that Cdk1 par-
ticipates in this inhibitory regulation (Kiyokawa et al., 1997;
Dangi and Shapiro, 2005). The situation is further compli-
cated by the fact that past studies on ERK1/2 activity at the
G2/M transition often used treatments with microtubule
inhibitors to obtain enriched fractions of mitotic cells, and
after treatment with these drugs some cell lines show ele-
vated levels of ERK1/2 activity (Schmid-Alliana et al., 1998;
Hayne et al., 2000), whereas others do not (Tamemoto et al.,
1992; Takenaka et al., 1998; Gomez-Cambronero, 1999). Thus,
the questions of whether activation of ERK1/2 near the end
of G2 and/or M is biologically relevant in mammals and
thus whether ERK1/2 plays a direct role in the G2/M tran-
sition remain controversial.
Finally, there are also reports that ERK1/2 activity is
required during mitosis in mammalian somatic cells, as it is
during meiosis in Xenopus oocytes, for proper spindle for-
mation and thus a timely metaphase-anaphase (M/A) tran-
sition (Willard and Crouch, 2001; Horne and Guadagno,
2003). In this regard, activated (phosphorylated) MEK1/2
and ERK1/2 are reported by immunofluorescence (IMF) to
be present during mitosis in centrosomes/spindle poles
(Shapiro et al., 1998; Liu et al., 2004; Lou et al., 2004) and
kinetochores (Shapiro et al., 1998; Zecevic et al., 1998) where
it is proposed to play a role in the SAC (Shapiro et al., 1998;
Willard and Crouch, 2001; Horne and Guadagno, 2003).
However, there is little data to support a functional role at
these locations and that which does is indirect and open to
different interpretations. Even the presence of active ERK1/2
on kinetochores is suspect, because not all IMF studies on
the distribution of active ERK1/2 during mitosis report it in
this location (Willard and Crouch, 2001), and popular anti-
bodies used to detect active MEK1/2 during mitosis (i.e.,
phosphorylated MEK1/2) can cross-react with another
phosphoprotein (Hayne et al., 2004). Also, a recent proteomic
analysis did not find ERK1/2 on isolated human metaphase
chromosomes, even though it identified 209 other chromo-
some-associated proteins (Uchiyama et al., 2005). Thus, the
question of whether active ERK1/2 is a component of kinet-
ochores, and, if so, whether its activity is required for SAC
function, also remains controversial.
To address the nontranscriptional role of ERK1/2 in the
G2/M and M/A transitions, we rapidly inhibited (or en-
hanced) ERK1/2 activity during late G2, just before mam-
malian cells become committed to mitosis, and followed the
cells by video light microscopy. This allowed us to directly
examine, for the first time, how inhibiting ERK1/2 during
late G2 affects the kinetics of the G2/M and M/A transitions,
independently of its role in initiating gene transcription
pathways earlier in G2. At the same time, we also explored
the requirement of ERK1/2 activity for the late G2 p38-
mediated “stress” checkpoint as well as the SAC. We also
conducted a series of microinjection, small interfering RNA
(siRNA), and ERK1/2 overexpression studies in an effort to
determine whether active ERK1/2 is really present at kinet-
ochores and centrosomes. Finally, using a unique assay for
G2 progression we asked whether the delay in the G2/M
transition (i.e., entering mitosis) seen by others in indirect
assays, in response to inhibiting ERK1/2, is due to a require-
ment for ERK1/2 activity during the early stages of G2.
MATERIALS AND METHODS
Cell Culture, Drug Treatment, and Live Cell Imaging
Telomerase-immortalized human retinal pigment epithelia 1 (RPE1), HeLa,
and rat kangaroo (PtK) cells were cultured in DMEM or Eagle’s minimal
essential medium (for PtK) supplemented with 10% fetal bovine serum (FBS).
BJ-ELB cells were cultured in a mixture of DMEM and Medium 1999 (4:1)
supplemented with 10% FBS. Human mammary epithelial cells (HMECs)
were maintained in MEGM (Clonetics BulletKits; Cambrex Bio Science,
Walkersville, MD) supplemented with 5 g/ml transferrin (Sigma-Aldrich,
St. Louis, MO) and 105 M isoproterenol (Sigma-Aldrich). U0126 (Promega,
Madison, WI), U0124 (Calbiochem, San Diego, CA), CI-1040 (Pfizer, Holland,
MI), nocodazole (Calbiochem), anisomycin (Calbiochem), and dimethyl sul-
foxide (DMSO) (Sigma-Aldrich) were added 15–30 min before each experi-
ments. To activate ERK1/2 with 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Cell Signaling Technology, Danvers, MA), cells were pretreated with 10 nM
TPA for 1 h and then with 50–100 nM TPA for 15 min according to the
manufacturer’s instructions. Our basic procedures for live cell imaging are
detailed in Khodjakov and Rieder (2006). Briefly, cells were cultured on
25-mm2 coverslips to 70 to 80% confluence, and the coverslips were assem-
bled into Rose Chambers 2 h before the start of each recording. Mid-to-late G2
cells, in which chromosome condensation is just evident by phase-contrast
light microscopy, were located and followed on a shuttered Diaphot 200
(Nikon, Melville, NY) microscope equipped with a Micromax camera (Roper
Scientific, Trenton, NJ). Images were acquired every 2–10 min and processed
by Image-Pro Plus (Media Cybernetics, Silver Spring, MD) and National
Institutes of Health ImageJ. The Rose chamber and microscope system were
maintained at 37°C throughout recording.
In some experiments, we used low magnification (10) phase-contrast
optics to follow fields of HeLa and NIH 3T3 cells for extended periods, before
and after treatment with ERK1/2 inhibitors, at an imaging rate of one image
every 5 min. These time-lapse sequences were then analyzed frame by frame,
at the individual cell level, to determine the number of cells within the field
that entered mitosis every 30 min (i.e., that exhibited nuclear envelope break-
down; NEB) as well as the duration of mitosis (NEB to the initiation of
cytokinesis). These data were then entered into the Excel spreadsheet pro-
gram (Microsoft, Redmond, WA) for statistical calculations. Each graph thus
generated incorporated data from at least four experiments (total number of
cells in all fields at least 2000).
Immunoblotting and Immunofluorescence
For Western blotting, cells were washed in ice-cold phosphate-buffered saline
(PBS), pH 7.4, containing 1 mM Na3VO4, lysed in cold lysis buffer (1% SDS, 20
mM HEPES, pH 7.4, 2 mM EGTA, 50 mM -glycerophosphate, 2 mM EDTA,
137.5 mM NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM Na3VO4, 40 M
phenylmethylsulfonyl fluoride, and Complete protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN), incubated for 10 min on ice, and
centrifuged at 14,000 rpm at 4°C. Equal amounts of protein (25 or 50 g) were
separated on SDS-PAGE gels, immunoblotted, and detected by enhanced
chemiluminescence.
For IMF analysis of CENP-F, cells were grown on coverslips to 50% con-
fluence, washed with PEM (100 mM PIPES, 2.5 mM EGTA, and 2 mM MgCl2,
pH 6.9), permeabilized with 0.2% Triton X-100, and fixed with 2% parafor-
maldehyde. For double IMF analysis of hemagglutinin (HA)-tag and CREST,
cells were washed with ice-cold PBS, pH 7.4, containing 1 mM Na3VO4, fixed
with 3% paraformaldehyde for 15 min on ice, and permeabilized with 0.1%
Triton-100 in PBS. For staining microtubules (MTs), cells were washed with
PEM, permeabilized with 1% Triton X-100, and fixed with 1% glutaraldehyde
in PEM. After fixation, the cultures were reduced by two 10-min treatments
with 1% sodium borohydride twice and then blocked with PBS containing 3%
bovine serum albumin (BSA). They were then incubated with primary anti-
bodies in PBS containing 0.05% Tween 20 and 1% BSA, pH 7.4, for 1 h at 37°C
M. Shinohara et al.
Molecular Biology of the Cell5228
and then with secondary antibodies labeled with Alexa Fluor 488 or 546
(Invitrogen, Carlsbad, CA) for 30 min at 37°C. DNA was stained with Hoechst
33342. All cells were imaged as a Z-series (200 nM apart) on an IX70 micro-
scope (Olympus America, Melville, NY), deconvolved as necessary using
Delta Vision 2.1 (Applied Precision, Issaquah, WA), and presented as maxi-
mal intensity projections.
The primary antibodies used in this study included rabbit Anti-ACTIVE
mitogen-activated protein kinase (MAPK) recognizing dually phosphorylated
ERK1/2 (pTEpY; Promega), mouse p-ERK antibody against ERK1/2 phos-
phorylated at Tyr-204 (E-4; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
p44/p42 MAPK antibody (Cell Signaling Technology) for detection of total
ERK1/2, rabbit anti-CENP-F (Calbiochem), His-tag antibody (Cell Signaling),
mouse anti-HA antibody (Roche Diagnostics, Indianapolis, IN), human anti-
kinetochore serum (CREST), p38 MAP kinase antibody (Cell Signaling Tech-
nology), anti-ACTIVE p38 (Promega), phospho-p53 antibodies (Ser15 and
Ser20; Cell Signaling Technology), p53 antibody (Cell Signaling Technology),
p21 Waf1/Cip1 antibody (clone DCS60; Cell Signaling Technology), Cyclin B1
antibody (sc-594; Santa Cruz Biotechnology), rabbit anti--tubulin (Sigma-
Aldrich), and mouse anti--tubulin (Sigma-Aldrich).
Isolation of Mitotic Cells
HeLa cells were grown in 100-mm dishes, and mitotic cells were separated
from those in interphase by mitotic shake off. Mitotic cells from five to 10
dishes were pooled and centrifuged. Cell pellets were rinsed with ice-cold
PBS, pH 7.4, containing 1 mM Na3VO4, lysed in cold lysis buffer, and used for
immunoblotting. To determine the percentage of mitotic cells in the mitotic
and interphase fractions, cell pellets were pipetted in hypotonic solution
(0.075 M KCl), incubated for 20 min, and fixed with methanol/acetic acid
(3:1). Cells were concentrated by centrifugation and resuspended in fixative,
spread onto glass slides and stained with Hoechst 33342.
Purification and Microinjection of Histidine-tagged
Wild-Type ERK2 in RPE1
His-tagged wild-type ERK2 (from Dr. Melanie Cobb, University of Texas
Southwestern Medical Center, Dallas, TX) was expressed in BL21 strain of
Escherichia coli and purified using His-Bind kits (Novagen, Madison, WI).
Purified ERK2 protein was dialyzed and concentrated to 1–10 g/l in
injection buffer (pH 7.7, 10 mM HEPES, 100 mM KCl, and 10% glycerol). The
kinase activity of purified His-ERK2 was confirmed by the nonradioactive
p44/42 MAP kinase assay kit (Cell Signaling Technology). RPE1 cells in late
prophase were microinjected with tagged ERK2. The cells were subsequently
fixed for IMF at various times after injection.
Transfection and Expression of HA-tagged ERK2 in RPE1
RPE1 cells were grown on coverslips in 35-mm culture dishes and transfected
with 1 g/dish of vector DNA containing HA-tagged ERK2 (Mainiero et al.,
1997) by using FuGENE 6 transfection reagent (Roche Diagnostics, Basel,
Switzerland). The activity of HA-ERK2 expressed in human cell lines has been
described previously (Aguirre Ghiso et al., 1999). After 24 or 48 h, cells were
fixed for IMF by using antibodies against HA and CREST as described above.
siRNA Knockdown of ERK1/2 in BJ-ELB Cells
BJ-ELB cells were kindly provided by Dr. Robert Weinberg (Whitehead
Institute for Biomedical Research, Cambridge, MA) and used with his per-
mission. These cells were grown on glass coverslips (for IMF) or without
coverslips (for Western blotting) and transfected with a mixture of SignalSi-
lence p42MAPK siRNA and p44MAPK siRNA (Cell Signaling Technology)
according to the manufacturer’s instructions. Control transfections were per-
formed with SignalSilence Control siRNA (fluorescein conjugate; Cell Signal-
ing Technology).
RESULTS
ERK1/2 Activity Is Not Required during Late G2 for
Normal Entry into or Exit from Mitosis
To determine how inhibiting ERK1/2 activity during late G2
affects the G2/M and M/A transitions, we used a live cell
assay to study these transitions in nontransformed mamma-
lian cell lines, RPE1 and PtK. For these studies, we defined
mitosis as the period from NEB to anaphase onset (chroma-
tid disjunction). Because chromosome condensation actually
begins during early G2 (Hendzel et al., 1997), and because
this process is fully reversible in mammals up until near the
time of NEB, we consider G2 and prophase as a continuous
phase of cell cycle that precedes mitosis (Pines and Rieder,
2001). In this assay, progress through prophase equals
progress through late G2 (Figure 1A). The advantage of this
live cell approach is that it provides direct qualitative (chro-
mosome structure and behavior) and quantitative (the du-
ration of late G2 and mitosis) data on how inhibiting or
activating ERK1/2 during late G2 influences the timing of
the G2/M and M/A transitions.
Initially, we asked how these transitions are affected when
ERK1/2 activation is prevented by U0126, a small molecule
inhibitor that prevents phosphorylation of ERK1/2 by allo-
steric binding to MEK1/2 (English and Cobb, 2002). To
avoid potential effects on gene expression, U0126 was added
to cultures of RPE1 and PtK cells 15–30 min before initiating
observations on cells in which chromosome condensation
was just evident. Western blotting of whole RPE1 and PtK
cell lysates revealed that a 15-min treatment with 25–50 M
U0126 effectively prevented ERK1/2 activation (phosphory-
lation) in both cell types (Figure 1B). Under these conditions
the duration of late G2 and mitosis was similar in both
U0126-treated and control cells (untreated or treated with 50
M U0124; Figure 1C and Table 1). In the absence of ERK1/2
activity, RPE1 and PtK cells also exhibited timely and nor-
mal chromosome condensation, spindle formation, chromo-
some congression, sister chromatid separation, and cytoki-
nesis (Figure 1C).
To confirm that inhibiting ERK1/2 has no specific effect on
mitotic progression, we repeated our experiments with CI-
1040 (PD184352), a more selective and potent inhibitor of
MEK. Although U0126 has been reported to also inhibit
ERK5 (Davies et al., 2000; Mody et al., 2001), CI-1040 selec-
tively inactivates ERK1/2 via MEK without inhibiting other
protein kinases, even at micromolar concentrations (Squires
et al., 2002). After a 15- to 30-min exposure to 100–300 nM of
this inhibitor, ERK1/2 activity was completely suppressed
in whole cell lysates of both PtK and RPE1 cells (Supple-
mental Figure S1), yet this inhibition did not affect the du-
ration of late G2, mitosis, or disrupt chromosome segrega-
tion (Supplemental Figure S1 and Table 1). Together, our
live cell assays reveal that ERK1/2 activity is not required
during late G2 for timely entry into or progression through
mitosis in normal mammalian somatic cells.
We next asked whether inhibiting ERK1/2 during late G2
delays entry into mitosis in mouse (NIH 3T3) and human
transformed cell lines (HeLa) previously used by others to
study the effects of long-term ERK1/2 inhibition on the cell
cycle. These cells are not readily amenable to live cell obser-
vations on the changes of chromatin structure during late
G2. As a result, for these experiments, we counted the num-
ber of cells entering mitosis and determined the duration of
mitosis in low-magnification video sequences 30 min after
inhibiting ERK1/2 activity with U0126 or CI-1040. The ra-
tionale here was that if ERK1/2 activity is required during
mid-to-late G2 for entry into or progression through mitosis,
then MEK inhibitors should immediately cause a noticeable
decrease in the rate at which cells enter mitosis and/or a
noticeable increase in the duration of mitosis. Although
these drugs completely inhibited ERK1/2 activity in HeLa
and 3T3 cells within 20 min (Figure 2A), they had no effect
during the first 4 h of treatment on the rate at which cells
entered mitosis, i.e., on the number of cells within the view-
ing field that underwent NEB (Figure 2B). In addition, we
saw no delay in completing mitosis, defined in this assay as
the period from NEB to the first signs of cytokinesis, in 3T3
or HeLa cells that entered mitosis in the absence of ERK
activity (Table 1). These findings on transformed cells are
consistent with our findings on normal cells (see above), and
they reveal that ERK1/2 activity is not needed during late
G2 for timely entry into or exit from mitosis in normal or
transformed cells.
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Figure 1. U0126 potently inhibits ERK1/2
activity but does not delay the G2/M or M/A
transitions in PtK or RPE1 cells. (A) We define
prophase as the terminal stage of G2, because
chromosome condensation can be reversed
before NEB. (B) A 15-min treatment with
10–50 M U0126, but not with DMSO or
U0124 (inactive analogue of U0126), was suf-
ficient to prevent ERK1/2 activation in PtK
and RPE1 cells. (C) Selected images from time
lapse recordings of PtK and RPE1 cells as they
progressed from late G2 through mitosis after
treatment with DMSO (control), 50 M U0124
(control), or U0126. Under all conditions RPE1
and PtK cells transition from G2 into mitosis
(as evidenced by NEB) after60 min and then
transited from metaphase to anaphase 20–35
min later. See Table 1 for mean durations.
Time is indicated in minutes before or after
nuclear envelope breakdown. Bar, 10 m.





MitosisLate G2 Mitosis Late G2 Mitosis
Controld 56.8  15.1 (n  13) 26.8  7.5 (n  76) 66.5  20.0 (n  32) 21.4  5.3 (n  32) 60.17  6.7 (n  179) 18.9  1.5 (n  71)
U0124 (50 M) 52.7  6.1 (n  9) 29.8  8.3 (n  20) 70.8  27.0 (n  16) 21.2  6.4 (n  20) N/A N/A
U0126 (50 M) 50.3  14.9 (n  13) 27.2  6.5 (n  20) 59.9  20.2 (n  7) 26.4  4.4 (n  17) 58.42  6.3 (n  78) 19.9  2.02 (n  96)
CI-1040 (100–300 nM) 55.7  3.7 (n  3) 24.7  2.9 (n  6) 73.7  19.3 (n  23) 22.0  7.7 (n  27) 68.64 15.4 (n  131) 19.1  1.39 (n  96)
a PtK cells include both PtK1 and PtK2.
b For PtK and RPE1, the duration of late G2 equals the period from the earliest visible sign of chromosome condensation to NEB, whereas
the duration of mitosis equals the period from NEB to the onset of anaphase. For HeLa and NIH 3T3, the duration of mitosis equals the period
from NEB to the onset of cytokinesis. Neither late G2 nor mitosis was delayed by inhibiting ERK1/2 with U0126 or CI-1040. U0124 is the
inactive analogue of U0126. Data are expressed as mean  SD.
c Data are expressed as mean  SEM of indicated number (n) of cells.
d Control cells were either untreated or treated with 2.5 l/ml DMSO.
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ERK1/2 Activity Is Required for Timely Progress through
Early–Mid-G2
It is well established that a sustained inhibition of ERK1/2
activity induces a delay in the G2/M transition (see Intro-
duction). However, in these studies cell cycle analyses were
based on the DNA content and Western blotting that does
not distinguish between early/mid-G2, late G2 (prophase) or
even mitosis. To determine more precisely when ERK1/2
activity is required during these periods, we treated grow-
ing unsynchronized RPE1 cultures with either 50 M U0126
(Figure 3A) or with 50 M U0124, an inactive analogue of
U0126. We then fixed RPE1 cultures at various time points
and immunostained them for centromere protein-F (CENP-F;
Liao et al., 1995). This kinetochore protein begins to accumu-
late in the nucleus during early G2 (and possibly late S), well
before chromosome condensation is microscopically evi-
dent. By late G2, it is concentrated in kinetochores and the
nuclear periphery (Liao et al., 1995). Using CENP-F as a
differential marker for the stages of G2, we counted RPE1
cells that were in early/mid-G2 (CENP-F positive, but no
visible chromatin condensation; Figure 3B), late G2 (chromo-
some condensation evident, CENP-F in the nucleus or local-
ized to the kinetochore and/or nuclear periphery) and mi-
tosis (prometaphase through telophase). To expand our
analysis to the whole cell cycle, we also counted the number
of cells in G1 and S (with basal CENP-F staining).
Although control cells showed similar cell cycle popula-
tion distributions at all time points (Figure 3C, top), we
found that the percentage of early G2 cells started to increase
shortly after treatment with U0126, and by 4 h it had dou-
bled (Figure 3C, bottom). This increase coincided with a
decrease in the percentage of G1-S, late G2 and mitotic cells.
After 4 h the percentage of G1-S cells started to increase, no
doubt because ERK1/2 activation is required for the G1/S
transition (Roovers and Assoian, 2000). Finally, after 24 h
most if not all of the cells were in G1 or S (or possibly in G0),
and no cells were in mitosis. The delay we observed in
early–mid-G2 is, however, transient, and after several hours
the cells resume cycling into mitosis and the next G0/G1/S,
where they are arrested. Thus, ERK1/2 activity is necessary
for timely progress through early/mid-G2, and in less direct
studies this delay is manifested as a delay in the “G2/M
transition.”
The Early G2 Delay Seen in Response to Inhibiting
ERK1/2 Is Mediated by p53
As a first step toward elucidating the molecular basis for the
early G2 delay seen after inhibiting the ERK1/2 pathway for
2–4 h, we examined the activity of negative regulators of the
cell cycle after inhibiting ERK1/2. We found that the level of
p38 expression and activity did not change over time after
ERK inhibition in RPE1 cells but that the level of active p53
(phosphorylated at Ser15 and Ser20) was elevated at 2 and
4 h after ERK1/2 inhibition by U0126 (Figure 4A). This
suggests that the early G2 delay in response to ERK1/2
inhibition is mediated by p53. To test this, we inhibited
ERK1/2 in growing cultures of HMECs that were p53/
or p53 deficient, and then we examined the distribution of
cells in the cycle with time. These studies revealed that, as
expected from the RPE1 work, cultures of p53/ HMEC
cells showed a significant increase in early G2 cells after
U0126 treatment (Figure 4B). By contrast, cultures of HMEC
cells lacking p53 showed no elevation in the number of G2
cells in response to U0126 treatment (Figure 4B). Together,
these data reveal that in the absence of ERK1/2 activity cells
are delayed in early/mid-G2 in a p53-dependent manner.
Because p21 expression did not increase in RPE1 cells after
ERK1/2 inhibition (Figure 4A), p53 seems to delay early/
mid-G2 progression independent of p21 induction.
Inhibiting ERK1/2 in Late G2 Does Not Impede Spindle
Formation
During our live cell studies, we saw no prolongation of
mitosis or enhanced abnormalities in chromosome motion
or distribution in response to the short-term inhibition of
ERK1/2 (via MEK1/2). After a 1-h treatment with 50 M
U0124 or 50 M U0126, PtK and RPE1 cultures, fixed and
stained for -tubulin and -tubulin IMF, contained normal
looking prometaphase, metaphase, anaphase, and telophase
figures, with no evidence of problems in chromosome seg-
regation (data not shown; Figure 1C). We also found that
normal bipolar spindles form in RPE1 and PtK cultures after
exposure to U0126 for much longer periods (2, 6, 12, and
24 h; Supplemental Figure S2). As with untreated cultures,
1% of the spindles seen in RPE1 cultures exposed up to
12 h to ERK1/2 inhibitors were abnormal (i.e., monopolar or
multipolar), and all of the cultures contained normal an-
Figure 2. Inhibiting ERK1/2 activity during late G2 in HeLa and
NIH 3T3 cultures does not retard entry into mitosis for at least
4 h. (A) Western blots demonstrating that treating HeLa or NIH
3T3 cultures with 50 M U0126 or 300 nM CI-1040 inhibits
ERK1/2 activity within 20 min. Time in minutes after inhibitor
addition is shown above the blots. (B) Graphs that plot the
percentage of total cells within a low power field of view (y-axis)
that enter mitosis every 30 min (i.e., that undergo nuclear enve-
lope breakdown), after inhibiting ERK1/2 activity with U0126 or
CI-1040, in HeLa and NIH 3T3 cultures. x-axis, time in hours after
addition of the inhibitor. Note that the rate at which HeLa and
NIH 3T3 cells enter mitosis does not change, relative to control
cultures, during the first 4 h after inhibiting ERK1/2.
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aphase and telophase cells as well as cells that had com-
pleted cytokinesis (data not shown). We also found no delay
in entering mitosis or exiting mitosis, or an increased inci-
dence of mitotic abnormalities, in NIH 3T3 or HeLa cells that
entered mitosis during the first 4–5 h after inhibiting
ERK1/2 (Figure 2B and Table 1; also see Supplemental Fig-
ure S5). Thus, ERK1/2 activity is not required during mid-
to-late G2 in mammalian cells for centrosome separation,
bipolar spindle assembly, chromosome segregation, or cyto-
kinesis.
ERK1/2 Localization and Activity during Mitosis
The question of whether ERK1/2 activity is enhanced dur-
ing mitosis, relative to interphase, remains controversial (see
Introduction). To explore this issue, we isolated mitotic frac-
tions of HeLa cells in asynchronously growing cultures by
Figure 3. Inhibiting ERK1/2 activity delays
progression through early–mid-G2. (A) Expos-
ing unsynchronized RPE1 cells to 50 M
U0126 inhibited phosphorylation (activation)
of ERK1/2 (ppERK1/2) for up to 24 h,
whereas the level of ERK1/2 expression re-
mains unaffected. (B) Cultures of RPE1 cells
were immunostained for CENP-F to differen-
tiate among G1-S (basal CENP-F expression,
top row), early/midG2 (CENP-F positive, but
chromatin condensation is not evident by
Hoechst staining, top row), and late G2 popu-
lations. In late G2 (prophase) cells, the chro-
mosomes are visibly condensing, and, de-
pending on this progress, CENP-F is either in
the nucleus (middle row) or concentrated on
the kinetochores and in nuclear periphery
(bottom row). (C) RPE1 cultures were treated
with 50 M U0126 or 50 M U0124 (control);
fixed after 0, 1, 2, 4, 8, 12 and 24 h; and then
stained for CENP-F. The percentage of cells in
G1-S, early–mid-G2, late G2, and mitosis (pro-
metaphase through telophase) was then deter-
mined and plotted. The percentage of G1-S
(CENP-F negative) cells is presented as bars,
and, relative to U0124-treated controls, pro-
gressively increases after 4 h in response to
inhibiting ERK1/2 until it reaches 100%. In the
same cultures, the number of early–mid-G2
cells doubles after 4 h in U0126, after which it progressively decreases as the cells overcome the delay and G1 cells fail to transit into S. At
least 6000 cells were counted per slide over three experiments, and values are given as the percentage cells  SD.
Figure 4. The early–mid-G2 delay in re-
sponse to ERK inhibition is mediated by p53.
(A) In RPE1 cells, the level of phosphorylated
p53 (at Ser15 and Ser20) increased after 2–4 h
of U0126 treatment, whereas expression of p21
and active p38 (pp-p38) remained constant. (B)
As in RPE1 cells (Figure 3), the early–mid-G2
cell population transiently increased in re-
sponse to inhibiting ERK1/2 withU0126 in
p53/ HMECs. By contrast, this response
was not seen in HMEC cells lacking p53. Note
that HMECs showed more rapid response to
U0126 than RPE1, which may be due to a
faster cell cycle. At least 3000 cells were
counted per slide, over three experiments, and
values are given as the percentage cells  SD.
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shake-off (Figure 5A) and compared the ERK1/2 activity by
Western blotting in mitotic and interphase cells. As shown
in Figure 5B, the mitotic cell fraction showed a significantly
lower level of phosphorylated ERK1/2 than the interphase
fraction. This finding is consistent with the reports of others
(see Introduction) that relative to interphase ERK1/2 activity
is diminished during mitosis.
Similarly, as reported previously (see Introduction), we
found that antibodies against singly (Santa Cruz Biotechnol-
ogy) or dually (Promega) phosphorylated ERK1/2 targeted
many (but by no means all) centromeric regions, centro-
somes, and midbodies when RPE1, PtK, and HeLa cells were
stained for IMF (Figure 6, top). Surprisingly, however, when
present the fluorescence signal was still strong on these
structures in cells treated with 50 M U0126 for 1, 2, 6, and
12 h, even though adjacent interphase cells showed only a
basal level of phosphorylated ERK1/2 (Figure 6, middle).
Likewise, when we treated cells with a pharmacological
activator of the ERK1/2 pathway (TPA; Supplemental Fig-
ure S3A) before IMF staining with the same antibodies
against active ERK1/2, the fluorescence signal was only
enhanced in interphase but not in mitotic cells (Figure 6,
bottom). This inability to pharmacologically regulate ERK1/2
activity during mitosis, combined with the known cross-
reactivity of many singly specific phosphorylation site anti-
bodies to other mitotic phosphoproteins, prompted us to ask
whether active ERK1/2 staining at kinetochores is an artifact
of IMF staining.
Figure 5. ERK1/2 activity is not enhanced during mitosis relative
to interphase. Mitotic cells were isolated from nonsynchronized
HeLa cultures by mitotic shake-off. The ERK1/2 activity in these
cells was then compared with the remaining interphase cells within
the culture by Western blots. (A) A representative example of mi-
totic HeLa cells obtained by shake-off. In three separate experi-
ments, the mitotic fraction contained 75–85% mitotic cells. (B) Rel-
ative to interphase cells, ERK1/2 activity was depressed during
mitosis in HeLa. Note also that ERK1/2 activity can be totally
suppressed during mitosis (and interphase) by a pretreatment with
U0126.
Figure 6. Active ERK1/2 staining on centro-
somes, centromeres, and midbodies does not
change when MEK1/2 is inhibited or acti-
vated. Immunofluorescence of untreated con-
trol RPE cells, by using an antibody against
singly phorphorylated ERK1/2 (E-4; Santa
Cruz Biotechnology), showed a nuclear signal
in interphase cells. By contrast in prophase
through anaphase cells active ERK1/2 was
concentrated in centromeres (inset, with
CREST staining), centrosomes, and midzones.
After a 2-h treatment with 50 M U0126, ac-
tive ERK1/2 was no longer detected in the
interphase cells, but it was still seen in late
prophase through anaphase cells. When cells
were treated with 50 nM TPA for 30 min, to
activate ERK1/2, the fluorescence signal was
notably increased in the nuclei of interphase
cells relative to control and U0126 treated cul-
tures, but not in mitotic cells. Bar, 10 m.
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Our initial approach to this question was to microinject
histidine-tagged active (as determined from kinase assays)
wild-type ERK2 into RPE1 cells during mid-prophase and
then fix the cells 15–30 min later (during prometaphase) for
IMF with an anti-His antibody. The rationale here was that
if ERK1/2 is a bona fide centromere and/or centrosome
component, the exogenous histidine-tagged ERK2 should
become incorporated into these structures. We found that,
although microinjected ERK2 was distributed throughout
the cytoplasm, it did not target centromeres or centrosomes
(Supplemental Figure S4). However, it may be that more
than 30-min is required for the His-tagged ERK2 to become
incorporated into kinetochores and centrosomes. To test this
possibility, we expressed a functional and activatable HA-
tagged ERK2 (Mainiero et al., 1997; Aguirre Ghiso et al., 1999;
Aguirre Ghiso, 2002) in RPE1 cells for 48 h (2 cell cycles) and
then examined its distribution by IMF. Again, we found that
although HA-ERK2 was present on the cytoskeleton and in
nuclei during interphase, as it should be (Gonzalez et al.,
1993; Reszka et al., 1995), it was not concentrated on centro-
meres or centrosomes during mitosis (Figure 7).
Finally, we studied the distribution of phosphorylated
ERK (pERK) during mitosis after knocking down the expres-
sion of ERK1 and -2 by using siRNA methods. To ensure
that the cells continued to cycle into mitosis during the
siRNA treatment, we performed these experiments in BJ-
ELB fibroblasts lacking functional pRb and p53 (Hahn et al.,
1999). Cells in this line continued to cycle without ERK1/2
expression (Supplemental Figure S5D). As in other cell
types, immunostaining of BJ-ELB fibroblasts with antibodies
to dually phosphorylated ERK produced a dot-like staining
concentrated in the chromosome area, with many dots co-
localizing on centromeres (i.e., CREST-stained regions; Sup-
plemental Figure S5B, left). Forty-eight hours after transfect-
ing cultures with siRNAs targeting ERK1 and ERK2, the
expression of ERK1/2 was significantly reduced, with the
level of pERK falling below 90% of that in control cells
Figure 7. HA-ERK2 does not localize to cen-
trosomes and centromeres. Top, after 24 h of
transfection in RPE1 cells, HA-ERK2 were ex-
pressed in 80% cells and associated predom-
inantly with the nucleus and the cytoskeleton
during interphase. Bottom, after 48 h (1–2 cell
cycles), cells were fixed and stained for HA
(green) and centromeres (CREST; red). Note
that in prometaphase and metaphase cells,
HA-ERK2 was distributed throughout the cy-
toplasm and intracellular spaces between
chromosomes, but it was not concentrated on
centrosomes or centromeres. Images were pre-
sented as z-stack maximal intensity projec-
tions.
Figure 8. Inhibiting ERK1/2 activity during late G2 does not pre-
vent activation of the p38 stress checkpoint. Top, treating RPE cells
with 18.8 nM anisomycin delayed progression through late G2 for
3–4 h, but cells ultimately entered and completed a normal mitosis.
Bottom, inhibiting ERK1/2 activity with 300 nM CI-1040, before
treatment with anisomycin, did not prevent the delay in late G2
induced by activating p38. Bar, 10 m.
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(Supplemental Figure S5A). However, many of the centro-
some and centromere regions of mitotic cells in cultures
depleted of ERK1/2 continued to stain positive for pERK
(Supplemental Figure S5B and C; 48 h). In these cultures, the
immunoreactivity pattern of the active pERK antibody per-
sisted, at the same level seen in controls, in spite of a signif-
icant reduction in the expression level and activity of the
target kinase.
The p38-mediated G2 and Spindle Assembly Checkpoints
Remain Functional in the Absence of ERK1/2 Activity
Although we found that ERK1/2 activity is not required
during late G2 for normal progression into and through
mitosis, it could still be involved in a cell cycle checkpoint
that is only apparent under defined conditions. G2 check-
point pathways function until the cell becomes committed to
mitosis during late prophase. These pathways are not con-
stitutively active but are quickly activated in response to
various stresses, including DNA damage and osmotic
shocks. Many of these insults delay cells in G2 by activating
p38 (Mikhailov et al., 2005). This prompted us to ask whether
ERK1/2 activity is needed for the p38-mediated checkpoint.
To answer this, we determined whether inhibiting ERK1/2
overrides the late G2 (prophase) delay induced by 18.8 nM
anisomycin, a potent p38 activator. As reported previously,
for PtK cells (Mikhailov et al., 2004), a 15-min treatment with
18.8 nM anisomycin prolongs the duration of late G2 by 3
h in RPE1 cells (Figure 8 and Table 2). However, when we
inhibited ERK1/2 activity with 300 nM of CI-1040 for 30 min
and then activated p38 with 18.8 nM anisomycin for 15 min,
the duration of prophase in RPE1 cells was similar to that
seen after anisomycin treatment alone (Figure 8 and Table
Figure 9. The spindle assembly checkpoint
remains functional in the absence of ERK1/2
activity. (A) Western blots showing that no-
codazole treatment (3 h; 50–100 nM) did not
change ERK1/2 activity in RPE cells and that
ERK1/2 activity was inhibited in nocodazole-
treated cells by U0126. (B) Top, 100 nM no-
codazole alone delays RPE cells in mitosis for
7 h (see Table 3). Middle, treating cells de-
layed for 3 h in mitosis by nocodazole, with
the ERK1/2 inhibitor, did not accelerate exit
from mitosis. Bottom, cells that enter mitosis
after a 1-h treatment with both 100 nM no-
codazole and U0126 were still delayed in mi-
tosis.
Table 2. ERK1/2 is not involved in the p38-mediated stress checkpoint
Control TPA (50–100 nM) Anisomycin (18.8 nM) CI-1040 (300 nM)  anisomycin (18.8 nM)
Late G2 66.5  20.0 (n  32) 69.1 24.0 (n  10) 185.8  72.7 (n  5) 170.2  62.5 (n  13)
Mitosis 21.4  5.3 (n  32) 23.7  3.6 (n  15) 18.3  2.8 (n  4) 19.5  2.4 (n  15)
RPE1 cells were treated with 18.8 nM anisomycin that prolongs late G2 by activating p38. Inhibiting ERK1/2 with 300 nM CI-1040 before
anisomycin treatment did not prevent this delay, implying that ERK1/2 activity is dispensable for the p-38-mediated G2 checkpoint pathway.
When RPE1 cells were treated with 50 or 100 nM TPA to activate ERK1/2, the duration of late G2 and mitosis was similar to that of control
cells. Data are expressed as mean  SD of indicated number (n) of cells.
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2). These results reveal that ERK1/2 activity is not required
for activation of the p38-mediated checkpoint during G2.
Next, we asked whether activating ERK1/2 during late G2
delays entry into mitosis, as does activating the p38 kinase.
For this study, we treated RPE1 cultures with 50 or 100 nM
TPA, which rapidly activates ERK1/2 via a growth factor
receptor-independent pathway, and then followed late G2
(early prophase) cells. Under this condition, we found that
TPA-treated RPE1 cells entered and exited mitosis with the
same timing as controls (Supplemental Figure S3 and Table
2). Thus, activating ERK1/2 does not delay progression
through late G2 or impede the G2/M transition.
The SAC acts constitutively during mitosis to ensure proper
spindle–kinetochore attachments, and agents that destabilize
MTs (like nocodazole) significantly prolong mitosis by imped-
ing satisfaction of the SAC (Rieder and Maiato, 2004). To de-
termine whether ERK1/2 activity is required for the SAC,
we treated RPE1 cells with nocodazole alone, or with no-
codazole and the MEK inhibitor U0126, and then followed
them to determine the duration of mitosis. Immunoblotting
revealed that 100 nM nocodazole for 3 h alone did not
change ERK1/2 activity in unsynchronized RPE1 cells and
also that U0126 suppressed ERK1/2 activity in the presence
of nocodazole (Figure 9A). We found that when RPE1 cells
were treated with 100 nM nocodazole, they remained in
mitosis for 6–7 h or occasionally 12 h (Figure 9B, top, and
Table 3). When ERK1/2 was inhibited 1 h before nocodazole
treatment and well before NEB (i.e., U0126 was added be-
fore kinetochore assembly), RPE1 cells were also arrested in
mitosis for 6–7 h or in some cases 12 h (Figure 9B, bottom,
and Table 3). In these cells, ERK1/2 activity was inhibited
well before the cell entered mitosis, yet the SAC remained
functional. Finally, when ERK1/2 was inhibited after cells
were arrested in mitosis for 3 h, the total duration of mitosis
was similar to that of cells treated with nocodazole alone
(Figure 9B, middle). From these observations, we conclude
that ERK1/2 activity is not required for generating or sus-
taining the SAC.
DISCUSSION
Unlike previous studies on the role of ERK1/2 in the cell
cycle, ours was designed to determine specifically if this
kinase plays a nontranscriptional role in controlling entry
into and exit from mitosis, i.e., whether ERK1/2 activity is
required directly during late G2 and/or mitosis in mamma-
lian somatic cells for, respectively, a timely G2/M and M/A
transition. To answer these questions, it was necessary to
rapidly and selectively inhibit the pathway at defined points
in the cell cycle, because prolonged suppression affects gene
expression. The two small molecule inhibitors of MEK1/2
(U0126 and CI-1040) used in our study were ideal for this
purpose, because they selectively reduce ERK1/2 activity to
undetectable levels on Western blots within 15–20 min (Fig-
ures 1B and 2A and Supplemental Figure S1A).
Unlike previous studies, we conducted our experiments
on both normal and transformed human cells, and we col-
lected data relevant to two separate issues: the requirement
for ERK1/2 activity during late G2 for a timely entry into
mitosis; and once in mitosis, its subsequent requirement for
proper spindle formation and the SAC. We have therefore
divided our discussion into two parts that reflect these sep-
arate problems. However, before this discussion it must be
noted that some of the apparently conflicting views on the
role of ERK1/2 in progression through G2 and mitosis come
from a less than precise use of already vague terms. A
number of studies, for example, conclude from indirect (i.e.,
flow cytometry and Western blotting) data that ERK1/2
activity is required for “mitotic progression.” However, in
these studies the term mitotic progression is used not in the
apparent and accepted meaning that it is required for timely
progress through mitosis (i.e., the M/A transition), but
rather that it is required for timely progress through the
“mitotic cycle” (through G2 into mitosis). Likewise, conclu-
sions that ERK1/2 activity is required for a normal G2/M
transition is interpreted by many to mean that ERK1/2
activity is needed during late G2 to activate the cyclin
B/Cdk1 kinase, which quickly leads to nuclear envelope
breakdown (entry into mitosis). However, in reality such
studies simply show that the G2/M transition is delayed,
relative to controls, in the absence of ERK1/2 activity. As a
result, studies concluding that inhibiting ERK1/2 delays/
disrupts the G2/M transition or mitotic progression often
really show only that inhibiting ERK1/2 during G2 delays
entry into mitosis. One final cautionary note: many fluores-
cence-activated cell sorting-based studies on the cell cycle
use, as a specific marker for mitosis, the anti-phosphohistone
H3 antibody. It should be understood, however, that 1)
mammalian cells are not “in mitosis” until they become
committed to the process at the very end of G2 (i.e., during
very late prophase; Pines and Rieder, 2001); and 2) H3
phosphorylation begins not during mitosis but instead dur-
ing very early G2 (Hendzel et al., 1997; Crosio et al., 2002). As
a result, those conclusions that inhibiting ERK1/2 affects the
duration of (or progression through) mitosis that are based
solely on fluorescence-activated cell sorting of phosphory-
lated H3 should be evaluated in light of these facts.
ERK1/2 Activity Is Required for Normal Progress through
Early-to-Mid- but Not Late G2
It is clear that inhibiting ERK1/2 during G2, by expressing
dominant-negative MEK or by RNAi, delays entry into mi-
tosis (see Introduction). However, because these approaches
take many hours to days to inactivate ERK1/2, a profound
impact on gene expression is unavoidable. Thus, it is possi-
ble that ERK1/2 activity is required only during early G2 to
Table 3. ERK1/2 activity is not required for a functional spindle assembly checkpoint
Control Nocodazole (100 nM) U0126 (50  M)  nocodazole (100 nM)
Mitosis 21.4 5.3 397.9 148.4 (n  9) 359.8 147.0 (n 24)
(n  32) 720 (n  4) 720 (n  5)
RPE1 cultures were treated with either nocodazole (100 nM) or with 50 M U0126 before nocodazole treatment. They were then followed
by time-lapse microscopy to determine the duration (in minutes) of mitosis (NEB to the anaphase onset). Nocodazole treatment prolonged
the duration of mitosis in the presence and absence of ERK1/2 activity by 6–7 h, or in some cells 12 h (720 min). Data are expressed as
mean  SD of indicated number (n) of cells.
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initiate a transcriptional program necessary for normal pro-
gression through G2 (and/or mitosis). Alternatively, it is just
as possible that ERK1/2 kinase activity is required for a
timely entry into mitosis because it is needed during late G2
to directly phosphorylate substrates involved in the G2/M
transition. Here, we show, by using live PtK, RPE1, HeLa,
and NIH 3T3 cells, that ERK1/2 activity is not required
during late G2 for a timely entry into mitosis. With the
exception of the statement in Horne and Guadagno (2003)
(p. 1024) that “the addition of the MEK inhibitor to [3T3]
cells synchronized at late G2 had little affect on entry into
mitosis as measured by the mitotic index (unpublished re-
sults),” this is a novel finding. Our data further reveal that
when ERK1/2 is suddenly inactivated in a culture of asyn-
chronously growing cells, the mitotic index gradually falls
over a 4- to 5-h period (Figures 3C and 4B). This observation
implies that ERK1/2 activity is required (at least in RPE and
HMEC P53/ cells) 4–5 h before NEB for normal cell cycle
(early G2) progression, but not after this time.
Progression through G2 is guarded by several cell cycle
checkpoints, mediated by the ataxia telangiectasia mutated/
ATM and Rad-3 related (ATM/ATR) and p38 kinases that
are triggered, respectively, by DNA damage or stress (for
review, see Mikhailov et al., 2005). Based on our live cell
studies, we conclude that ERK1/2 activity is not required for
a functional p38 checkpoint pathway: in the absence of
ERK1/2 activity, early prophase cells are still delayed from
entering mitosis when p38 is activated with anisomycin
(Figure 8 and Table 2). Several studies have, however, sug-
gested that ERK1/2 activity is required for the cell cycle
arrest, and subsequent fate (survival/apoptosis) of cells,
when DNA is damaged during G2 (Abbott and Holt, 1999;
Tang et al., 2002; Yan et al., 2005). We are currently exploring
the possibility that ERK1/2 interfaces with the ATM/ATR
complex during DNA damage in late G2.
The dispensability of ERK1/2 activity during late G2 for a
timely G2/M transition suggests that the delay in entering
mitosis seen in longer term ERK1/2 inhibition studies is due
to a requirement for ERK1/2 activity during earlier G2. To
explore this idea, we used an assay for progression through
G2, based on CENP-F staining (Liao et al., 1995), to deter-
mine where cells are delayed in G2 when ERK1/2 is acutely
inhibited. We found that that inhibiting ERK1/2 in normal
human RPE1 and HMEC cultures causes a transient (4- to
5-h) delay in early–mid-G2, which is then manifested as a
retardation of the mitotic index 4–5 h later (Figure 3). This
too is also a novel finding, which could not be obtained from
less direct population studies that lack the ability to discrim-
inate between early–mid- and late G2 (or even mitotic) cells.
Finally, using biochemical assays and isogenic cell lines, we
found that this transient delay is mediated by p53 but ap-
parently not via the p21 pathway (Figure 4).
Our conclusion that ERK1/2 activity is required during
early–mid-G2 for timely progress toward mitosis is actually
consistent with the conclusion of previous studies reporting
that ERK1/2 activity is needed for a timely G2/M transition
(see Introduction and above). However, we find that the
requirement for ERK1/2 activity occurs during early–mid-
G2, and not at the G2/M border, and that it is this require-
ment that is manifested in less direct studies as a delay in the
G2/M transition. The reason why ERK1/2 activity is re-
quired during early–mid-G2 for normal cell cycle progres-
sion remains vague. Although active MEK and ERK are
thought to be necessary for Golgi disassembly in prepara-
tion for mitosis (Jesch et al., 2001), recent observations sug-
gest this process is really mediated by ERK1c, a spliced
isoform of ERK1 (Shaul and Seger, 2006). Furthermore,
Golgi dispersion occurs during very late G2, near the time
the cell becomes committed to entering mitosis. ERK1/2 is
also reported to activate topoisomerase II (Shapiro et al.,
1999) and the SWI/SNF complex (Sif et al., 1998), both of
which are required during G2 for normal structural changes
in chromatin. Thus, it is possible modifications in the acti-
vation of these complexes lead to a temporary delay in
early–mid-G2. A more attractive explanation, however, is
that the transient delay seen during early–mid-G2 in re-
sponse to inhibiting ERK1/2 arises from a requirement for
this kinase in mitosis-activating factors, such as FoxM1, that
ignite gene transcription programs required for normal cell
cycle progression (Laoukili et al., 2005). However, regardless
of the mechanism, our data clearly reveal that the activity of
ERK1/2 during early–mid-G2 is not an absolute requirement
for entry into mitosis, i.e., after 4–5 h the cell “adapts” to the
absence of ERK1/2 function and resumes cycling into mito-
sis. Thus, unlike for the G1/S transition, ERK1/2 activity is
not an absolute requirement for progression through G2.
ERK1/2 Activity Is Not Required during Mitosis for
Normal Spindle Assembly or for a Functional Spindle
Assembly Checkpoint
We found that when ERK1/2 activity is inhibited during late
G2, normal and transformed human cells form normal bipo-
lar spindles, segregate sister chromatids, and exit mitosis
with normal timing (Figures 1C and 2B, Table 1, and Sup-
plemental Figure S1B). Indeed, relative to interphase cells,
we found as others have (Newberry and Pike, 1995;
Kiyokawa et al., 1997; Klein et al., 1997; Dangi and Shapiro,
2005) that ERK1/2 activity is diminished during mitosis
(Figure 5). In our study, we found no evidence that inhibit-
ing ERK1/2 activity during late G2 or M disrupts spindle
assembly and function in NIH 3T3, HeLa, PtK, or RPE1 cells,
even in those cells that entered mitosis after a 4- to 5-h delay
in early–mid-G2 due to a lack of ERK1/2 activity (Supple-
mental Figure S2). This conclusion conflicts with that of
Horne and Guadagno (2003) who report that a short-term (2-
to 3-h) treatment with U0126 leads to a higher incidence of
“abnormal spindles” in NIH 3T3 cells. However, the pheno-
types reported by these researchers resemble normal inter-
mediates in bipolar spindle assembly, and no attempt was
made to compare the numbers of prometaphase, metaphase,
anaphase, and multipolar spindles seen after drug treatment
with those of nondrug-treated control cultures. In this re-
gard, we found that inhibiting ERK1/2 with U0126, in the
absence of nocodazole treatment, had no effect on the dura-
tion of mitosis in 3T3 (or any other cell type examined). As
in our study, Roberts et al. (2002) also reported that inhibit-
ing MEK1/2 (ERK1/2) with U0126 or PD184352 has no
deleterious long-term effects on spindle assembly in HeLa or
RPE1 cells.
Given our conclusions that inhibiting ERK1/2 activity
during G2 does not prolong mitosis or disrupt spindle as-
sembly in mammalian cells, we were not surprised to find
that inhibiting ERK1/2 activity during late G2 or mitosis did
not affect the workings of the SAC (Figure 9 and Table 3).
Again, this conclusion seems to conflict with reports that
inhibiting ERK1/2 in NIH 3T3 (Willard and Crouch, 2001) or
HeLa (Roberts et al., 2002) cells delays the M/A transition. In
the case of NIH 3T3, this conclusion was based on the
observation that mitotic cells do not recover from a 12-h
nocodazole block over a 2-h period after being released
directly into U0126. However, no controls were run to show
that the M/A delay seen in response to the second drug
(U0126) was due to the specific inhibition of MEK1/2 and
not to toxicity (or to a requirement for ERK1/2 activity in
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ridding the cells of nocodazole via p-glycoprotein drug
pumps). We repeated the Willard and Crouch study, in the
absence of a nocodazole pretreatment, and found that inhib-
iting ERK1/2 activity during late G2 (also with U0126) had
no effect on the duration of mitosis (Table 1). In the case of
HeLa (Roberts et al., 2002), the conclusion that inhibiting
ERK1/2 delays the M/A transition was based on comparing
the mitotic index of control and drug (PD184352)-treated
cultures, fixed at various time intervals after releasing from
a thymidine block. We note, however, that the transient
delay in early–mid-G2 in response to inhibiting ERK1/2 seen
in our study produces a decrease in the mitotic index in
HMEC cultures 3- to 4-h postdrug treatment, which is then
followed by a sudden conspicuous increase at the 6-h time
point (Figure 4B). This exact same behavior is seen 2.5 and
5 h after releasing synchronized HeLa cells into U0126 (Fig-
ure 6D in Roberts et al., 2002), and at the 5-h interval, there
are actually many more cells in mitosis (including prophase)
than in nondrug-treated controls. We suggest that this in-
creased mitotic index arises not from a delayed progression
through mitosis as concluded by Roberts et al. (2002), but
instead from a bolus of cells entering mitosis after a transient
delay in early–mid-G2 due to a lack of ERK1/2 activity.
ERK1/2 is constitutively present throughout the cell cycle
and at any given time the extent of its activity is defined by
a balance between regulatory kinases and phosphatases
(Widmann et al., 1999). Based on our biochemical results, we
were surprised to find that we could not pharmacologically
regulate ERK1/2 activity (i.e., the phospho ERK1/2 level) at
centromeres or centrosomes during mitosis, even when we
applied inhibitors or activators before active ERK1/2 stain-
ing is apparent at these structures (in early-to-mid-prophase;
see Shapiro et al., 1998; Zecevic et al., 1998). The reason for
this is unknown, and there are at least two possibilities. First,
it may be that once ERK1/2 becomes associated with cen-
tromeres and centrosomes it can no longer be pharmacolog-
ically regulated, e.g., its activation may become MEK-inde-
pendent or the protein may not be accessible to regulatory
phosphatases. Alternatively, as noted in the Introduction the
active ERK1/2 signal seen by IMF at centromeres and cen-
trosomes may be an immunological artifact. This possibility
is consistent with our biochemical data that phosphorylated
ERK1/2 is not detectable both in interphase and mitotic cells
treated with U0126 (Figure 5B), and with our finding that
ERK1/2 does not play a role during mitosis in spindle
assembly, the M/A transition or the SAC. It is also sup-
ported by our His–ERK2 microinjection, HA–ERK2 overex-
pression and siRNA studies that, although individually con-
sistent, are admittedly not without potential sources of error.
Indeed, in spite of our efforts there is an inherent problem
with proving that a protein does not reside at a specific
location, because the proof must rely on negative data—and
evidence of absence is not proof of absence.
Finally, the constitutive activation ERK1/2, via its up-
stream activator Ras, leads to a high incidence of errors
during mitosis (Saavedra et al., 1999; Knauf et al., 2006). Yet,
we found that aberrant activation of ERK1/2 during late G2
has no immediate effect on spindle formation or chromo-
some segregation. This suggests that the genetic instability
associated with constitutive ERK1/2 activation arises pri-
marily from a requirement for ERK activity during or before
early G2. In this regard, unscheduled entry into S phase
leads to replication stress, which activates the DNA damage
checkpoint. In turn, this leads to a block in S and G2, which
then generates aberrant DNA contents (Bartkova et al., 2005).
Because mutational activation of Raf is seen in many tumor
cells (Davies et al., 2002), ERK1/2 pathway inhibitors have
been extensively studied as potential therapeutic options.
Indeed, MEK inhibitors have proven effective at suppressing
proliferation, and CI-1040 used in our study entered phase II
clinical trials (Sebolt-Leopold and Herrera, 2004). Our data
imply that these drugs delay the cell cycle in noncancerous
cells predominantly at G1/S and that they do not induce
aberrant mitosis when applied during G2. It remains to be
seen whether nontumor cells become genetically unstable
after prolonged exposures to these inhibitors.
ACKNOWLEDGMENTS
We are indebted to Melanie Cobb (University of Texas Southwestern Medical
Center) for providing the recombinant ERK2 construct, Pfizer for providing
CI-1040, Martha R. Stampfer (Lawrence Berkeley National Laboratory, Life
Sciences Division, Berkeley, CA) for providing the HMEC cell lines, and
Robert Weinberg (Whitehead Institute for Biomedical Research, Cambridge,
MA) for providing BJ-ELB cells. We also express sincere gratitude to Drs.
Alexey Khodjakov, Erasmus Schneider (Wadsworth Center), and Donald
Porter (Ordway Research Institute, Albany, NY) for helpful suggestions and
discussions. This research was supported by National Institutes of Health
Grant GMS-40198 to C.L.R., by National Institutes of Health/National Cancer
Institute Grant CA109182, and Samuel Waxman Cancer Research Foundation
grants to J.A.A.-G.
REFERENCES
Abbott, D. W., and Holt, J. T. (1999). Mitogen-activated protein kinase kinase
2 activation is essential for progression through the G2/M checkpoint arrest
in cells exposed to ionizing radiation. J. Biol. Chem. 274, 2732–2742.
Aguirre Ghiso, J. A. (2002). Inhibition of FAK signaling activated by urokinase
receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21,
2513–2524.
Aguirre Ghiso, J. A., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy
induced by downregulation of urokinase receptor in human carcinoma in-
volves integrin and MAPK signaling. J. Cell Biol. 147, 89–104.
Alvarez, B., Martinez, A. C., Burgering, B. M., and Carrera, A. C. (2001).
Forkhead transcription factors contribute to execution of the mitotic pro-
gramme in mammals. Nature 413, 744–747.
Bartkova, J., et al. (2005). DNA damage response as a candidate anti-cancer
barrier in early human tumorigenesis. Nature 434, 864–870.
Chung, E., and Chen, R. H. (2003). Phosphorylation of Cdc20 is required for
its inhibition by the spindle checkpoint. Nat. Cell Biol. 5, 748–753.
Crosio, C., Fimia, G. M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S.,
Allis, C. D., and Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone
H 3, spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell.
Biol. 22, 874–885.
Dangi, S., and Shapiro, P. (2005). Cdc2-mediated inhibition of epidermal
growth factor activation of the extracellular signal-regulated kinase pathway
during mitosis. J. Biol. Chem. 280, 24524–24531.
Davies, H., et al. (2002). Mutations of the BRAF gene in human cancer. Nature
417, 949–954.
Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and
mechanism of action of some commonly used protein kinase inhibitors.
Biochem. J. 351, 95–105.
Edelmann, H. M., Kuhne, C., Petritsch, C., and Ballou, L. M. (1996). Cell cycle
regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in
Swiss mouse 3T3 fibroblasts. J. Biol. Chem. 271, 963–971.
English, J. M., and Cobb, M. H. (2002). Pharmacological inhibitors of MAPK
pathways. Trends Pharmacol Sci 23, 40–45.
Ferrell, J. E., Jr. (1999). Xenopus oocyte maturation: new lessons from a good
egg. Bioessays 21, 833–842.
Giroux, S., et al. (1999). Embryonic death of Mek1-deficient mice reveals a role
for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr.
Biol. 9, 369–372.
Gomez-Cambronero, J. (1999). P42-MAP kinase is activated in EGF-stimu-
lated interphase but not in metaphase-arrested HeLa cells. FEBS Lett. 443,
126–130.
Gonzalez, F. A., Seth, A., Raden, D. L., Bowman, D. S., Fay, F. S., and Davis,
R. J. (1993). Serum-induced translocation of mitogen-activated protein kinase
to the cell surface ruffling membrane and the nucleus. J. Cell Biol. 122,
1089–1101.
M. Shinohara et al.
Molecular Biology of the Cell5238
Gotoh, Y., Nishida, E., Matsuda, S., Shiina, N., Kosako, H., Shiokawa, K.,
Akiyama, T., Ohta, K., and Sakai, H. (1991). In vitro effects on microtubule
dynamics of purified Xenopus M phase-activated MAP kinase. Nature 349,
251–254.
Grill, C., Gheyas, F., Dayananth, P., Jin, W., Ding, W., Qiu, P., Wang, L., Doll,
R. J., and English, J. M. (2004). Analysis of the ERK1,2 transcriptome in
mammary epithelial cells. Biochem. J. 381, 635–644.
Guadagno, T. M., and Ferrell, J. E., Jr. (1998). Requirement for MAPK activa-
tion for normal mitotic progression in Xenopus egg extracts. Science 282,
1312–1315.
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks,
M. W., and Weinberg, R. A. (1999). Creation of human tumour cells with
defined genetic elements. Nature 400, 464–468.
Harding, A., Giles, N., Burgess, A., Hancock, J. F., and Gabrielli, B. G. (2003).
Mechanism of mitosis-specific activation of MEK1. J. Biol. Chem. 278, 16747–
16754.
Hayne, C., Tzivion, G., and Luo, Z. (2000). Raf-1/MEK/MAPK pathway is
necessary for the G2/M transition induced by nocodazole. J. Biol. Chem. 275,
31876–31882.
Hayne, C., Xiang, X., and Luo, Z. (2004). MEK inhibition and phosphorylation
of serine 4 on B23 are two coincident events in mitosis. Biochem. Biophys. Res.
Commun. 321, 675–680.
Hendzel, M. J., Wei, Y., Mancini, M. A., Van Hooser, A., Ranalli, T., Brinkley,
B. R., Bazett-Jones, D. P., and Allis, C. D. (1997). Mitosis-specific phosphory-
lation of histone H3 initiates primarily within pericentromeric heterochroma-
tin during G2 and spreads in an ordered fashion coincident with mitotic
chromosome condensation. Chromosoma 106, 348–360.
Horne, M. M., and Guadagno, T. M. (2003). A requirement for MAP kinase in
the assembly and maintenance of the mitotic spindle. J. Cell Biol. 161, 1021–
1028.
Jesch, S. A., Lewis, T. S., Ahn, N. G., and Linstedt, A. D. (2001). Mitotic
phosphorylation of Golgi reassembly stacking protein 55 by mitogen-acti-
vated protein kinase ERK2. Mol. Biol. Cell 12, 1811–1817.
Khodjakov, A., and Rieder, C. L. (2006). Imaging the division process in living
tissue culture cells. Methods 38, 2–16.
Kiyokawa, N., Lee, E. K., Karunagaran, D., Lin, S. Y., and Hung, M. C. (1997).
Mitosis-specific negative regulation of epidermal growth factor receptor, trig-
gered by a decrease in ligand binding and dimerization, can be overcome by
overexpression of receptor. J. Biol. Chem. 272, 18656–18665.
Klein, S., Kaszkin, M., Barth, H., and Kinzel, V. (1997). Signal transduction
through epidermal growth factor receptor is altered in HeLa monolayer cells
during mitosis. Biochem. J. 322, 937–946.
Knauf, J. A., Ouyang, B., Knudsen, E. S., Fukasawa, K., Babcock, G., and
Fagin, J. A. (2006). Oncogenic RAS induces accelerated transition through
G2/M and promotes defects in the G2 DNA damage and mitotic spindle
checkpoints. J. Biol. Chem. 281, 3800–3809.
Laird, A. D., Morrison, D. K., and Shalloway, D. (1999). Characterization of
Raf-1 activation in mitosis. J. Biol. Chem. 274, 4430–4439.
Laoukili, J., Kooistra, M. R., Bras, A., Kauw, J., Kerkhoven, R. M., Morrison,
A., Clevers, H., and Medema, R. H. (2005). FoxM1 is required for execution of
the mitotic programme and chromosome stability. Nat. Cell Biol. 7, 126–136.
Liao, H., Winkfein, R. J., Mack, G., Rattner, J. B., and Yen, T. J. (1995). CENP-F
is a protein of the nuclear matrix that assembles onto kinetochores at late G2
and is rapidly degraded after mitosis. J. Cell Biol. 130, 507–518.
Liu, X., Yan, S., Zhou, T., Terada, Y., and Erikson, R. L. (2004). The MAP
kinase pathway is required for entry into mitosis and cell survival. Oncogene
23, 763–776.
Lou, Y., Xie, W., Zhang, D. F., Yao, J. H., Luo, Z. F., Wang, Y. Z., Shi, Y. Y., and
Yao, X. B. (2004). Nek2A specifies the centrosomal localization of Erk2.
Biochem. Biophys. Res. Commun. 321, 495–501.
Ma, R. Y., Tong, T. H., Cheung, A. M., Tsang, A. C., Leung, W. Y., and Yao,
K. M. (2005). Raf/MEK/MAPK signaling stimulates the nuclear translocation
and transactivating activity of FOXM1c. J. Cell Sci. 118, 795–806.
Mainiero, F., Murgia, C., Wary, K. K., Curatola, A. M., Pepe, A., Blumemberg,
M., Westwick, J. K., Der, C. J., and Giancotti, F. G. (1997). The coupling of
alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls
keratinocyte proliferation. EMBO J. 16, 2365–2375.
Mikhailov, A., Shinohara, M., and Rieder, C. L. (2004). Topoisomerase II and
histone deacetylase inhibitors delay the G2/M transition by triggering the p38
MAPK checkpoint pathway. J. Cell Biol. 166, 517–526.
Mikhailov, A., Shinohara, M., and Rieder, C. L. (2005). The p38-mediated
stress-activated checkpoint. A rapid response system for delaying progression
through antephase and entry into mitosis. Cell Cycle 4, 57–62.
Minshull, J., Sun, H., Tonks, N. K., and Murray, A. W. (1994). A MAP
kinase-dependent spindle assembly checkpoint in Xenopus egg extracts. Cell
79, 475–486.
Mody, N., Leitch, J., Armstrong, C., Dixon, J., and Cohen, P. (2001). Effects of
MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502,
21–24.
Newberry, E. P., and Pike, L. J. (1995). Cell-cycle-dependent modulation of
EGF-receptor-mediated signaling. Biochem. Biophys. Res. Commun. 208, 253–
259.
Pages, G., Lenormand, P., L’Allemain, G., Chambard, J. C., Meloche, S., and
Pouyssegur, J. (1993). Mitogen-activated protein kinases p42mapk and
p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA
90, 8319–8323.
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman,
K., and Cobb, M. H. (2001). Mitogen-activated protein (MAP) kinase path-
ways: regulation and physiological functions. Endocr. Rev. 22, 153–183.
Pines, J., and Rieder, C. L. (2001). Re-staging mitosis: a contemporary view of
mitotic progression. Nat. Cell Biol. 3, E3–E6.
Reszka, A. A., Seger, R., Diltz, C. D., Krebs, E. G., and Fischer, E. H. (1995).
Association of mitogen-activated protein kinase with the microtubule cy-
toskeleton. Proc. Natl. Acad. Sci. USA 92, 8881–8885.
Rieder, C. L., and Maiato, H. (2004). Stuck in division or passing through:
what happens when cells cannot satisfy the spindle assembly checkpoint.
Dev. Cell 7, 637–651.
Roberts, E. C., Shapiro, P. S., Nahreini, T. S., Pages, G., Pouyssegur, J., and
Ahn, N. G. (2002). Distinct cell cycle timing requirements for extracellular
signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in
somatic cell mitosis. Mol. Cell. Biol. 22, 7226–7241.
Roovers, K., and Assoian, R. K. (2000). Integrating the MAP kinase signal into
the G1 phase cell cycle machinery. Bioessays 22, 818–826.
Saavedra, H. I., Fukasawa, K., Conn, C. W., and Stambrook, P. J. (1999).
MAPK mediates RAS-induced chromosome instability. J. Biol. Chem. 274,
38083–38090.
Schmid-Alliana, A., Menou, L., Manie, S., Schmid-Antomarchi, H., Millet,
M.-A., Giuriato, S., Ferrua, B., and Rossi, B. (1998). Microtubule integrity
regulates Src-like and extracellular signal-regulated kinase activities in hu-
man pro-monocytic cells. J. Biol. Chem. 273, 3394–3400.
Sebolt-Leopold, J. S., and Herrera, R. (2004). Targeting the mitogen-activated
protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937–947.
Seger, R., and Krebs, E.G. (1995). The MAPK signaling cascade. FASEB J. 9,
726–735.
Shapiro, P. S., Vaisberg, E., Hunt, A. J., Tolwinski, N. S., Whalen, A. M.,
McIntosh, J. R., and Ahn, N. G. (1998). Activation of the MKK/ERK pathway
during somatic cell mitosis: direct interactions of active ERK with kineto-
chores and regulation of the mitotic 3F3/2 phosphoantigen. J. Cell Biol. 142,
1533–1545.
Shapiro, P. S., Whalen, A. M., Tolwinski, N. S., Wilsbacher, J., Froelich-
Ammon, S. J., Garcia, M., Osheroff, N., and Ahn, N. G. (1999). Extracellular
signal-regulated kinase activates topoisomerase IIalpha through a mechanism
independent of phosphorylation. Mol. Cell. Biol. 19, 3551–3560.
Shaul, Y. D., and Seger, R. (2006). ERK1c regulates Golgi fragmentation
during mitosis. J. Cell Biol. 172, 885–897.
Sif, S., Stukenberg, P. T., Kirschner, M. W., and Kingston, R. E. (1998). Mitotic
inactivation of a human SWI/SNF chromatin remodeling complex. Genes
Dev. 12, 2842–2851.
Squires, M. S., Nixon, P. M., and Cook, S. J. (2002). Cell-cycle arrest by
PD184352 requires inhibition of extracellular signal-regulated kinases (ERK)
1/2 but not ERK5/BMK1. Biochem. J. 366, 673–680.
Takenaka, K., Gotoh, Y., and Nishida, E. (1997). MAP kinase is required for
the spindle assembly checkpoint but is dispensable for the normal M phase
entry and exit in Xenopus egg cell cycle extracts. J. Cell Biol. 136, 1091–1097.
Takenaka, K., Moriguchi, T., and Nishida, E. (1998). Activation of the protein
kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 280,
599–602.
Tamemoto, H., Kadowaki, T., Tobe, K., Ueki, K., Izumi, T., Chatani, Y., Kohno,
M., Kasuga, M., Yazaki, Y., and Akanuma, Y. (1992). Biphasic activation of
two mitogen-activated protein kinases during the cell cycle in mammalian
cells. J. Biol. Chem. 267, 20293–20297.
ERK1/2 and Mitosis in Mammals
Vol. 17, December 2006 5239
Tang, D., Wu, D., Hirao, A., Lahti, J. M., Liu, L., Mazza, B., Kidd, V. J., Mak,
T. W., and Ingram, A. J. (2002). ERK activation mediates cell cycle arrest and
apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710–
12717.
Uchiyama, S., et al. (2005). Proteome analysis of human metaphase chromo-
somes. J. Biol. Chem. 280, 16994–17004.
Wang, X. M., Zhai, Y., and Ferrell, J. E., Jr. (1997). A role for mitogen-activated
protein kinase in the spindle assembly checkpoint in XTC cells. J. Cell Biol.
137, 433–443.
Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999). Mitogen-
activated protein kinase: conservation of a three-kinase module from yeast to
human. Physiol. Rev. 79, 143–180.
Willard, F. S., and Crouch, M. F. (2001). MEK, ERK, and p90RSK are present
on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in
regulating mitotic exit. Cell Signal. 13, 653–664.
Wojnowski, L., Stancato, L. F., Zimmer, A. M., Hahn, H., Beck, T. W., Larner,
A. C., Rapp, U. R., and Zimmer, A. (1998). Craf-1 protein kinase is essential for
mouse development. Mech. Dev. 76, 141–149.
Wright, J. H., Munar, E., Jameson, D. R., Andreassen, P. R., Margolis, R. L.,
Seger, R., and Krebs, E. G. (1999). Mitogen-activated protein kinase kinase
activity is required for the G(2)/M transition of the cell cycle in mammalian
fibroblasts. Proc. Natl. Acad. Sci. USA 96, 11335–11340.
Yan, Y., Spieker, R. S., Kim, M., Stoeger, S. M., and Cowan, K. H. (2005).
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Oncogene 24, 3285–3296.
Yoon, S., and Seger, R. (2006). The extracellular signal-regulated kinase:
multiple substrates regulate diverse cellular functions. Growth Factors 24,
21–44.
Zecevic, M., Catling, A. D., Eblen, S. T., Renzi, L., Hittle, J. C., Yen, T. J.,
Gorbsky, G. J., and Weber, M. J. (1998). Active MAP kinase in mitosis:
localization at kinetochores and association with the motor protein CENP-E. J.
Cell Biol. 142, 1547–1558.
M. Shinohara et al.
Molecular Biology of the Cell5240
